GLPG1205 for idiopathic pulmonary fibrosis: a Phase 2 randomised placebo-controlled trial.
Irina R StrambuChristian A SeemayerLiesbeth M-C A FagardPaul A FordTom A K Van der AaAngela A de Haas-AmatsalehVikas ModgillEva SantermansEric N SondagEric G HelmerToby M MaherUlrich CostabelVincent CottinPublished in: The European respiratory journal (2022)
placebo. GLPG1205 demonstrated a poorer safety and tolerability profile than placebo.